Abstract library

260 results for "SS analogue".
#190 Complete Remission in a Patient with Metastatic Type 1 Gastric Carcinoid (GCA1) Treated with a Long-acting Somatostatin Analogue
Introduction: Surgery is the treatment of choice for invasive and metastatic GCA1. Somatostatin analogues have been successfully used in GCA1 patients without signs of malignancy.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr merav Fraenkel
#313 Effect of Somatostatin Analogues in the Control of Tumor Growth in Patients with Metastatic Lung Carcinoid Tumors
Introduction: Antitumor effect of Somatostatin analogues has been poorly documented in metastatic typical or atypical lung carcinoid tumors (LCT).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Joël Guigay
#14 Radioguided surgery in NET: First impression with Ga-68 labeled somatostatin analogues
Introduction: Neuroendocrine tumors (NET) constitute a heterogenous group of neoplasms. The development of Gallium-68-labeled somatostatin analogues, such as DOTA-NOC or DOTA-TOC, PET/CT have dramatically improved the diagnosis of neuroendocrine tumors. Surgery remains the treatment of choice for localized disease as well as metastatic disease. The aims of surgery are: improvement of symptoms, reduction of tumor mass / burden and to give better quality of life to patients. Recurrent laparotomies often lead to multiple adhesions and altered anatomy. So it is increasingly difficult for imaging physicians and surgeons to separate non-malignant from malignant tissue.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
#82 A case of insulinoma successfully treated by means of long-acting somatostatin analogue
Introduction: Insulinoma is the most common hormonally active pancreatic neuroendocrine tumor. Effective treatment represents tumor surgery and medical therapy using diazoxide or streptozotocine. Somatostatin analogue therapy is rarely effective in this type of tumor.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Marek Bolanowski
#148 Near-complete regression of liver metastatic lesions in a patient with advanced pancreatic gastrinoma in response to somatostatin analogue therapy following cytoreductive surgery
Introduction: Although the majority of pancreatic NETs present with hepatic metastases, surgery with curative intent should be the first consideration. Cytoreductive surgery by resection of primary and secondary deposits may be of value in achieving local or endocrine symptoms control.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Dorota Dworakowska
Authors: Dworakowska D, Whyte M, Kane P, Patel A, ...
#436 Role of Somatostatin Analogues in the Management of Merkel Cell Carcinoma: A Case Report
Introduction: Merkel cell carcinoma (MCC) is a relatively rare neuroendocrine malignant tumor that is characterized by an aggressive course with regional nodal involvement, distant metastases and a high rate of recurrence.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Kristina Orlova
#1375 Merkel Cell Carcinoma of the Knee Treated with Somatostatin Analogue and Radiotherapy: A Case Report
Introduction: Merkel cell carcinoma (MCC) is a rare and aggressive primary cutaneous neuroendocrine malignancy. Chemotherapy with cisplatin (CDDP) and etoposide (VP16) is an effective treatment for metastatic MCC.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Ivana Puliafito
#1488 Chemoprevention with a Long Acting Somatostatin Analogue in a Multiple Endocrine Neoplasia Type 1 (MEN1) Knockout Mouse Model Does Delay the Progression of Pancreatic Neuroendocrine Neoplasms (pNENs)
Introduction: Long acting somatostatin analogues (LAR) are an essential part of the treatment of neuroendocrine tumours.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: MD Caroline Lopez
#2888 Progression-Free Survival as a Surrogate Endpoint in Gastroenteropancreatic Neuroendocrine Tumors Treated with Somatostatin Analogues
Introduction: Progression-free survival (PFS) has been used as surrogate endpoint in phase III trials with somatostatin analogues for gastroentero-pancreatic neuroendocrine tumors (GEP-NET). However, this endpoint has not been validated in this scenario.
Conference: 17th Annual ENETS Conference (2020)
Category: Medical treatment - others, not specified
Presenting Author: Alberto Carmona-Bayonas
#44 Somatostatin analogue therapy and RAND-36 health-related quality of life scores in patients with neuroendocrine tumors
Introduction: Somatostatin analogues (SSAs) are used in patients with neuroendocrine tumors (NETs) for the management of carcinoid syndrome and/or delay of disease progression.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Yao J C, Beaumont J L, Choi S, Cella D, ...
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team